icometrix
icometrix develops FDA-cleared AI software (the icobrain platform) that automates brain MRI analysis for neurological disorders including multiple sclerosis, Alzheimer's disease, and stroke, serving 400+ hospitals across 30+ countries; acquired by GE HealthCare in November 2025.
- Company typePrivate
- Founded2011
- HeadquartersLeuven, Belgium
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What icometrix does
icometrix is a Belgian medical-imaging AI company founded in 2011 in Leuven, Belgium, that develops the icobrain platform — FDA-cleared and CE-marked software that uses deep learning to automatically detect, segment, and quantify brain structures and lesions from MRI scans. The product portfolio spans disease-specific modules for multiple sclerosis (icobrain ms), Alzheimer's disease and dementia (icobrain dm), amyloid-related imaging abnormalities tied to anti-amyloid therapy safety monitoring (icobrain aria, the first FDA-cleared AI for ARIA detection), stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors, plus the icobridge PACS/EMR integration middleware and the icompanion.ms patient-facing mobile medical device. The platform is deployed at 400+ hospitals across 30+ countries, with regulatory clearance in 28 countries, and is supported by >270 peer-reviewed scientific publications and a proprietary RECLAIM database holding >55,000 MRI scans from >7,500 MS patients.
The company generates revenue primarily through enterprise SaaS subscriptions to hospitals and academic medical centers for clinical icobrain deployment, and through clinical-trial and research-services engagements with pharmaceutical companies and research institutions using icobrain as a standardized imaging biomarker. Pricing is quotation-based and enterprise-negotiated on annual subscription terms; in the U.S. market, icobrain analysis is reimbursable through CPT-III codes 0865T/0866T processed by >30 insurers. Customer segments are diversified across three verticals — clinical hospitals and neurology/radiology departments, pharmaceutical and biotechnology companies running neurological clinical trials, and academic research institutions — with go-to-market executed via direct enterprise sales, medical-conference presence (RSNA, ECTRIMS, AAIC, ISMRM), and a network of strategic partnerships with medical societies and patient organizations.
In September 2025 GE HealthCare announced its intent to acquire icometrix, completing the transaction in November 2025; icometrix now operates as a wholly-owned GE HealthCare subsidiary, with the icobrain platform positioned to be distributed through GE's global MRI installed-base sales channel alongside ongoing direct enterprise relationships. Wim Van Hecke remains CEO.
icometrix firmographics
Firmographics- Name
- icometrix
- Legal name
- icometrix NV
- Website
- https://icometrix.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- icometrix develops FDA-cleared AI software (the icobrain platform) that automates brain MRI analysis for neurological disorders including multiple sclerosis, Alzheimer's disease, and stroke, serving 400+ hospitals across 30+ countries; acquired by GE HealthCare in November 2025.
- Ownership category
- akta.pro rank
icometrix industry classification
Industry- Product category
- AI Brain MRI Imaging Software
- NAICS
- Software Publishers (513210), Software Publishers (5132)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Medical Imaging AI (HDAAAEAH)
Keywords
Where icometrix is headquartered
LocationHeadquarters
- HQ city
- Leuven
- HQ country
- Belgium
- HQ region
- Europe
Offices2 records
Markets served
icometrix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Software licensing and subscriptions: icometrix generates revenue through licensing its FDA-cleared and CE-marked icobrain AI software to hospitals, research centers, and pharmaceutical companies. Fees are typically annual subscriptions with renewal terms, with pricing tied to usage volume or institutional agreements. The company also supports reimbursement through CPT-III codes 0865T/0866T for AI-assisted MRI analysis in the U.S. market.
- Clinical trial and research services: Revenue generated from pharmaceutical companies and research institutions using icobrain technology for clinical trials, drug development studies, and real-world evidence generation in neurological conditions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise institutional licensing |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
icometrix product offering
Product offeringCore offering
icometrix develops and licenses the icobrain AI-powered brain imaging analysis platform, which automatically detects, segments, and quantifies brain structures and lesions from MRI scans across multiple neurological conditions including multiple sclerosis, Alzheimer's disease, ARIA monitoring, stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors. The software is sold as annual subscriptions to hospitals, academic medical centers, research institutions, and pharmaceutical companies, complemented by icobridge for PACS/EMR integration and icompanion.ms as an FDA-cleared mobile app for MS patients.
Product overview
icometrix offers a unified AI-powered brain imaging platform centered on icobrain, with disease-specific modules including icobrain ms (multiple sclerosis), icobrain aria (Alzheimer's ARIA monitoring), and icobrain dm (dementia/Alzheimer's). The portfolio includes icobridge for PACS/EMR integration and icompanion.ms for patient engagement. All solutions are FDA-cleared, CE-marked, and validated across 400+ hospitals in 30+ countries.
Differentiator
Problem solved
Functional benefit
Brands
- icobrain: AI-powered brain imaging analysis platform providing automated detection, segmentation, and quantification of brain structures and lesions to support clinicians and researchers in neurological disorders. Includes modules for MS (icobrain ms), dementia/Alzheimer's (icobrain dm), ARIA detection (icobrain aria), stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors.
- icobridge
- icompanion.ms
Products and services
- icobrain AI-powered brain imaging analysis platform that automatically detects, segments, and quantifies brain structures and lesions from MRI scans to support clinical decision-making in neurology across multiple sclerosis, Alzheimer's, stroke, TBI, epilepsy, Parkinson's, and brain tumors.
- icobrain ms FDA-cleared and CE-marked MRI analysis solution for multiple sclerosis that provides lesion burden quantification, brain volume monitoring, and longitudinal comparison to support MS diagnosis and treatment decisions.
- icobrain aria FDA-cleared AI solution specifically designed to detect, measure, and grade amyloid-related imaging abnormalities (ARIA-E and ARIA-H) in patients receiving anti-amyloid Alzheimer's therapies, supporting safe treatment monitoring.
- icobrain dm
Quantifiable outcome
- 150% increase in detection of disease activity in MS
- +5 more outcomes
Companies that use icometrix
Customer profileNamed customers9 records
Segments4 records
Ideal customer profiles4 records
icometrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability5 records
Feature7 records
icometrix partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship and core.
- Multiple Sclerosis Association of America (MSAA)flagshipPartnership to expand MSAA's MRI Access Program, supporting approximately 1,000 MRI scans annually for individuals with MS experiencing financial or systemic barriers. icometrix provides AI-powered MRI analysis through icobrain ms technology for disease progression tracking and treatment effectiveness evaluation.
- AstraZenecacoreicometrix collaborates with AstraZeneca and MENACTRIMS on AI-driven initiative aiming to improve NMOSD (Neuromyelitis Optica Spectrum Disorder) diagnosis across the Middle East & Africa region.
- NVIDIAcoreOngoing collaboration with NVIDIA as part of GE HealthCare's broader innovation partnerships to develop advanced imaging, AI-enabled diagnostics, and cloud-based solutions for healthcare.
- GE HealthCarecoreGE HealthCare announced intent to acquire icometrix in September 2025 for undisclosed terms, completing the acquisition in November 2025. The deal integrates icometrix's icobrain AI platform with GE HealthCare's MRI systems to strengthen clinical decision support for neurological care, particularly Alzheimer's disease treatment monitoring.
- Charité - Universitätsmedizin BerlincoreCoordinator of the European CLAIMS project (Clinical Impact through AI-assisted MS Care) involving 15 organizations. icometrix provides quantitative MRI analysis of the >55,000 MRI scans in the RECLAIM database from >7,500 individuals with MS.
- ASST Papa Giovanni XXIIIcoreItalian public institution contributing clinical data, MRI scans and examinations from over 400 patients to the European RECLAIM research study on MS within the CLAIMS project. European Commission awarded budget of €200,000 for the project.
- American College of Radiology (ACR)flagshipACR and icometrix entered strategic collaboration to improve quality of care for Alzheimer's disease patients. ALZ-NET participating imaging facilities receive discounted access to icobrain aria solution. Collaboration includes educational initiatives and standardized ARIA monitoring across the network.
- InRAD (International Registry for Alzheimer's Disease)flagshipStrategic collaboration to improve standardization of real-world evidence generation and care for Alzheimer's disease patients receiving disease-modifying therapies. Long-term objectives include integrating pseudonymized imaging outcomes into the InRAD registry for those using the icometrix pipeline.
- PhilipsflagshipPhilips integrated icometrix AI solutions into its next-generation BlueSeal helium-free MRI system as part of its AI-enabled Smart Workflow solutions. Philips developed this partnership to offer cloud-based AI reading tools for neurological diagnostics alongside Quibim for prostate cancer diagnostics.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
icometrix competitors and assessment
Company assessmentDirect peers
- Cortechs.ai: Direct competitor in AI-powered brain MRI analysis, with FDA-cleared NeuroQuant for brain volumetrics and similar disease modules (MS, Alzheimer's, TBI) sold to radiology departments of hospital systems.
- Viz.ai: AI radiology platform with neuro-focused modules (LVO stroke, aneurysm, PE) deployed across hospital systems, increasingly competing with icometrix in neurology AI workflows and the same enterprise radiology buyer.
- RapidAI: AI platform for neurovascular and stroke imaging with FDA-cleared modules overlapping icometrix's stroke and broader neurology offering, sold to the same hospital radiology and neurology customers.
- Aidoc: Enterprise radiology AI suite with multiple FDA-cleared modules including neuro (ICH, stroke); competes with icometrix for the same hospital enterprise imaging AI budget and PACS integration workflows.
- Quibim: AI medical imaging company with FDA-cleared QP-Prostate and broader MRI analysis modules; partner of Philips alongside icometrix and competes in the same imaging-AI category sold to hospital radiology.
- Blackford Analysis: Medical imaging AI platform offering a marketplace and curated AI applications for radiology, including neuro modules, serving the same hospital and enterprise imaging buyer.
Emerging players
- Annalise.ai: AI radiology platform with comprehensive chest and emerging neuro CT/MRI modules; addresses overlapping radiology workflows and competes for similar enterprise imaging AI contracts.
- Neosoma: AI software for brain tumor analysis and longitudinal monitoring on MRI — directly overlaps with icometrix's icobrain brain tumor module in the same neuro-oncology imaging workflow.
- Subtle Medical: AI imaging company focused on MRI image enhancement and workflow acceleration; adjacent to icometrix as it operates at the MRI acquisition stage and partners with similar hospital radiology customers and modality vendors.
Broad incumbents
- Brainlab: Larger established neuroimaging and surgical planning software provider with Elements software family; overlaps with icometrix in neuro quantitative imaging and broader neurology hospital software sales.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
icometrix social profiles
Digital presenceicometrix compliance and trust
Trust signalCompliance6 records
icometrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
icometrix leadership team
Management profileNumber of profiles
Profiles6 records
icometrix funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
icometrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about icometrix
What does icometrix do?
icometrix develops and licenses the icobrain AI-powered brain imaging analysis platform, which automatically detects, segments, and quantifies brain structures and lesions from MRI scans across multiple neurological conditions including multiple sclerosis, Alzheimer's disease, ARIA monitoring, stroke, traumatic brain injury, epilepsy, Parkinson's disease, and brain tumors. The software is sold as annual subscriptions to hospitals, academic medical centers, research institutions, and pharmaceutical companies, complemented by icobridge for PACS/EMR integration and icompanion.ms as an FDA-cleared mobile app for MS patients.
Is icometrix a public or private company?
icometrix is a private company. It is classified as corporate owned and is currently acquired.
When was icometrix founded?
icometrix was founded in 2011. It employs 11 to 50 people.
Where is icometrix based?
icometrix is headquartered in Leuven, Belgium, in the Europe region.
How does icometrix make money?
Two revenue lines are on record. Software licensing and subscriptions are the primary driver. The others are clinical trial and research services.
Who are icometrix's main competitors?
Direct peers on record are Cortechs.ai, Viz.ai, RapidAI, Aidoc, Quibim and Blackford Analysis. Emerging players are Annalise.ai, Neosoma and Subtle Medical. Brainlab is listed as a broad incumbent.
Does icometrix have an API?
No public API is recorded for icometrix.
What industry is icometrix in?
icometrix's product category is AI Brain MRI Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 513210 and its SIC code is 7372.